Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Parallax by Ankur Kalra and Radcliffe Cardiology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Parallax by Ankur Kalra and Radcliffe Cardiology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

EP 144: ESC 25 in Review with Dr Purvi Parwani

1:05:25
 
Share
 

Manage episode 513469414 series 2657277
Content provided by Parallax by Ankur Kalra and Radcliffe Cardiology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Parallax by Ankur Kalra and Radcliffe Cardiology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
In this evidence-packed episode of Parallax, Dr Ankur Kalra welcomes back Dr Purvi Parwani, Associate Professor of Medicine at Loma Linda University Health, for a comprehensive review of groundbreaking trials presented at the European Society of Cardiology Congress. Dr Parwani guides listeners through what she describes as a "tectonic shift" in post-MI care with the REBOOT and BETAMI-DANBLOCK trials. These studies challenge the routine use of beta blockers after heart attack, revealing that patients with preserved ejection fraction above 50% may not benefit, while those with EF between 40-49% show significant risk reduction from continued therapy. The discussion moves to heart failure management, exploring the POTCAST trial's approach to optimising potassium levels in high-risk patients and the DIGIT-HF trial's examination of digitoxin as a potential option for patients who cannot tolerate modern four-pillar therapy. Dr Kalra and Dr Parwani conclude with the evolving role of aspirin in cardiovascular care. They discuss findings from NEO-MINDSET, TARGET-FIRST, and the AQUATIC trial, which together are reshaping antiplatelet strategies from the immediate post-PCI period through long-term management of stable coronary disease in patients requiring anticoagulation. Questions and comments can be sent to "[email protected]" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.
  continue reading

145 episodes

Artwork
iconShare
 
Manage episode 513469414 series 2657277
Content provided by Parallax by Ankur Kalra and Radcliffe Cardiology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Parallax by Ankur Kalra and Radcliffe Cardiology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
In this evidence-packed episode of Parallax, Dr Ankur Kalra welcomes back Dr Purvi Parwani, Associate Professor of Medicine at Loma Linda University Health, for a comprehensive review of groundbreaking trials presented at the European Society of Cardiology Congress. Dr Parwani guides listeners through what she describes as a "tectonic shift" in post-MI care with the REBOOT and BETAMI-DANBLOCK trials. These studies challenge the routine use of beta blockers after heart attack, revealing that patients with preserved ejection fraction above 50% may not benefit, while those with EF between 40-49% show significant risk reduction from continued therapy. The discussion moves to heart failure management, exploring the POTCAST trial's approach to optimising potassium levels in high-risk patients and the DIGIT-HF trial's examination of digitoxin as a potential option for patients who cannot tolerate modern four-pillar therapy. Dr Kalra and Dr Parwani conclude with the evolving role of aspirin in cardiovascular care. They discuss findings from NEO-MINDSET, TARGET-FIRST, and the AQUATIC trial, which together are reshaping antiplatelet strategies from the immediate post-PCI period through long-term management of stable coronary disease in patients requiring anticoagulation. Questions and comments can be sent to "[email protected]" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.
  continue reading

145 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play